A detailed history of Lindbrook Capital, LLC transactions in Organon & Co. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 2,780 shares of OGN stock, worth $41,060. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,780
Previous 3,206 13.29%
Holding current value
$41,060
Previous $66,000 19.7%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$18.65 - $23.03 $7,944 - $9,810
-426 Reduced 13.29%
2,780 $53,000
Q2 2024

Jul 31, 2024

BUY
$17.45 - $21.96 $19,299 - $24,287
1,106 Added 52.67%
3,206 $66,000
Q1 2024

Apr 25, 2024

BUY
$13.78 - $18.8 $3,610 - $4,925
262 Added 14.25%
2,100 $39,000
Q4 2023

Jan 31, 2024

BUY
$10.95 - $17.32 $15,636 - $24,732
1,428 Added 348.29%
1,838 $26,000
Q3 2023

Oct 25, 2023

SELL
$16.59 - $23.77 $1,526 - $2,186
-92 Reduced 18.33%
410 $7,000
Q2 2023

Jul 28, 2023

SELL
$19.27 - $24.63 $8,401 - $10,738
-436 Reduced 46.48%
502 $10,000
Q1 2023

Apr 26, 2023

BUY
$21.42 - $32.08 $9,189 - $13,762
429 Added 84.28%
938 $22,000
Q4 2022

Jan 24, 2023

SELL
$23.31 - $28.61 $1,655 - $2,031
-71 Reduced 12.24%
509 $0
Q3 2022

Nov 10, 2022

SELL
$23.4 - $34.25 $3,907 - $5,719
-167 Reduced 22.36%
580 $14,000
Q2 2022

Aug 01, 2022

BUY
$31.66 - $38.9 $601 - $739
19 Added 2.61%
747 $25,000
Q1 2022

Apr 21, 2022

BUY
$30.45 - $39.36 $7,825 - $10,115
257 Added 54.56%
728 $25,000
Q4 2021

Jan 18, 2022

BUY
$28.67 - $37.13 $1,634 - $2,116
57 Added 13.77%
471 $14,000
Q3 2021

Nov 05, 2021

SELL
$28.63 - $35.64 $2,347 - $2,922
-82 Reduced 16.53%
414 $14,000
Q2 2021

Jul 27, 2021

BUY
$28.45 - $38.0 $14,111 - $18,848
496 New
496 $15,000

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $3.76B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.